Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | bb2121: a promising outlook for the future of multiple myeloma

Howard Burris • 14 Jun 2018
ASCO 2018
Multiple Myeloma bb2121 CAR-T
CRB-401

The CRB-401 trial (NCT02658929) aims to investigate the efficacy of bb2121 for multiple myeloma (MM) patients. In this interview, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, outlines the preliminary results of the trial and speaks about the possible advances that could be made as a result.

More from Howard Burris

2:46
The use and benefits of liquid biopsy
Howard Burris • 3 Jun 2016
1:59
TGR-1202 in CLL and non-Hodgkin lymphoma
Howard Burris • 3 Jun 2016

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals